{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:23:37Z","timestamp":1791091417776,"version":"4.1.0"},"reference-count":45,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8,1]]},"abstract":"<jats:p>OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of erythropoietin in neonatal hypoxic-ischemic encephalopathy (HIE), by using a randomized, prospective study design.<\/jats:p>\n                  <jats:p>METHODS: A total of 167 term infants with moderate\/severe HIE were assigned randomly to receive either erythropoietin (N = 83) or conventional treatment (N = 84). Recombinant human erythropoietin, at either 300 U\/kg (N = 52) or 500 U\/kg (N = 31), was administered every other day for 2 weeks, starting &amp;lt;48 hours after birth. The primary outcome was death or disability. Neurodevelopmental outcomes were assessed at 18 months of age.<\/jats:p>\n                  <jats:p>RESULTS: Complete outcome data were available for 153 infants. Nine patients dropped out during treatment, and 5 patients were lost to follow-up monitoring. Death or moderate\/severe disability occurred for 35 (43.8%) of 80 infants in the control group and 18 (24.6%) of 73 infants in the erythropoietin group (P = .017) at 18 months. The primary outcomes were not different between the 2 erythropoietin doses. Subgroup analyses indicated that erythropoietin improved long-term outcomes only for infants with moderate HIE (P = .001) and not those with severe HIE (P = .227). No negative hematopoietic side effects were observed.<\/jats:p>\n                  <jats:p>CONCLUSION: Repeated, low-dose, recombinant human erythropoietin treatment reduced the risk of disability for infants with moderate HIE, without apparent side effects.<\/jats:p>","DOI":"10.1542\/peds.2008-3553","type":"journal-article","created":{"date-parts":[[2009,7,27]],"date-time":"2009-07-27T07:32:55Z","timestamp":1248679975000},"page":"e218-e226","source":"Crossref","is-referenced-by-count":297,"title":["Erythropoietin Improved Neurologic Outcomes in Newborns With Hypoxic-Ischemic Encephalopathy"],"prefix":"10.1542","volume":"124","author":[{"given":"Changlian","family":"Zhu","sequence":"first","affiliation":[{"name":"Departments of Pediatrics"},{"name":"Henan Key Laboratory for Neonatal Brain Injury, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Zhengzhou Children's Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falin","family":"Xu","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"},{"name":"Henan Key Laboratory for Neonatal Brain Injury, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"},{"name":"Henan Key Laboratory for Neonatal Brain Injury, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Neonatal Brain Injury, Zhengzhou, China"},{"name":"Laboratory Medicine, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Jia","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Neonatal Brain Injury, Zhengzhou, China"},{"name":"Laboratory Medicine, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ji","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Guo","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Zhengzhou Children's Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Simbruner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics IV Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas","family":"Blomgren","sequence":"additional","affiliation":[{"name":"Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Pediatric Oncology, Queen Silvia Children's Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"},{"name":"Henan Key Laboratory for Neonatal Brain Injury, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,8,1]]},"reference":[{"key":"2021120905302672200_R1","doi-asserted-by":"crossref","unstructured":"Johnston MV, Nakajima W, Hagberg H. Mechanisms of hypoxic neurodegeneration in the developing brain. Neuroscientist.\u20082002;8(3):212\u2013220","DOI":"10.1177\/1073858402008003007"},{"key":"2021120905302672200_R2","doi-asserted-by":"crossref","unstructured":"Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med.\u20082005;353(15):1574\u20131584","DOI":"10.1056\/NEJMcps050929"},{"key":"2021120905302672200_R3","doi-asserted-by":"crossref","unstructured":"Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet.\u20082005;365(9460):663\u2013670","DOI":"10.1016\/S0140-6736(05)70932-6"},{"key":"2021120905302672200_R4","doi-asserted-by":"crossref","unstructured":"Gunn AJ, Gunn TR, Gunning MI, Williams CE, Gluckman PD. Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep. Pediatrics.\u20081998;102(5):1098\u20131106","DOI":"10.1542\/peds.102.5.1098"},{"key":"2021120905302672200_R5","doi-asserted-by":"crossref","unstructured":"Silverman WA, Fertig JW, Berger AP. The influence of the thermal environment upon the survival of newly born premature infants. Pediatrics.\u20081958;22(5):876\u2013886","DOI":"10.1542\/peds.22.5.876"},{"key":"2021120905302672200_R6","doi-asserted-by":"crossref","unstructured":"Maier RF, Obladen M, Scigalla P, et al. The effect of epoetin \u03b2 (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N Engl J Med.\u20081994;330(17):1173\u20131178","DOI":"10.1056\/NEJM199404283301701"},{"key":"2021120905302672200_R7","doi-asserted-by":"crossref","unstructured":"Ohls RK, Ehrenkranz RA, Das A, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics.\u20082004;114(5):1287\u20131291","DOI":"10.1542\/peds.2003-1129-L"},{"key":"2021120905302672200_R8","doi-asserted-by":"crossref","unstructured":"Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A.\u20082000;97(19):10526\u201310531","DOI":"10.1073\/pnas.97.19.10526"},{"key":"2021120905302672200_R9","doi-asserted-by":"crossref","unstructured":"Casals-Pascual C, Idro R, Gicheru N, et al. High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. Proc Natl Acad Sci U S A.\u20082008;105(7):2634\u20132639","DOI":"10.1073\/pnas.0709715105"},{"key":"2021120905302672200_R10","doi-asserted-by":"crossref","unstructured":"Wang X, Zhu C, Wang X, et al. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem.\u20082004;91(4):900\u2013910","DOI":"10.1111\/j.1471-4159.2004.02769.x"},{"key":"2021120905302672200_R11","doi-asserted-by":"crossref","unstructured":"Chang YS, Mu D, Wendland M, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res.\u20082005;58(1):106\u2013111","DOI":"10.1203\/01.PDR.0000163616.89767.69"},{"key":"2021120905302672200_R12","doi-asserted-by":"crossref","unstructured":"McPherson RJ, Demers EJ, Juul SE. Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology.\u20082007;91(1):36\u201343","DOI":"10.1159\/000096969"},{"key":"2021120905302672200_R13","doi-asserted-by":"crossref","unstructured":"Wen TC, Rogido M, Peng H, Genetta T, Moore J, Sola A. Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats. Neuroscience.\u20082006;139(3):803\u2013811","DOI":"10.1016\/j.neuroscience.2006.02.057"},{"key":"2021120905302672200_R14","doi-asserted-by":"crossref","unstructured":"Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics.\u20082006;118(3). Available at: www.pediatrics.org\/cgi\/content\/full\/118\/3\/e635","DOI":"10.1542\/peds.2005-3186"},{"key":"2021120905302672200_R15","doi-asserted-by":"crossref","unstructured":"Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med.\u20082002;8(8):495\u2013505","DOI":"10.1007\/BF03402029"},{"key":"2021120905302672200_R16","doi-asserted-by":"crossref","unstructured":"Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood.\u20082000;95(9):2983\u20132989","DOI":"10.1182\/blood.V95.9.2983.009k27_2983_2989"},{"key":"2021120905302672200_R17","doi-asserted-by":"crossref","unstructured":"Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress: a clinical and electroencephalographic study. Arch Neurol.\u20081976;33(10):696\u2013705","DOI":"10.1001\/archneur.1976.00500100030012"},{"key":"2021120905302672200_R18","doi-asserted-by":"crossref","unstructured":"Thompson CM, Puterman AS, Linley LL, et al. The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. Acta Paediatr.\u20081997;86(7):757\u2013761","DOI":"10.1111\/j.1651-2227.1997.tb08581.x"},{"key":"2021120905302672200_R19","doi-asserted-by":"crossref","unstructured":"Amiel-Tison C, Ellison P. Birth asphyxia in the full-term newborn: early assessment and outcome. Dev Med Child Neurol.\u20081986;28(5):671\u2013682","DOI":"10.1111\/j.1469-8749.1986.tb03914.x"},{"key":"2021120905302672200_R20","unstructured":"Bao XL, Yu RJ, Li ZS. 20-item neonatal behavioral neurological assessment used in predicting prognosis of asphyxiated newborn. Chin Med J (Engl).\u20081993;106(3):211\u2013215"},{"key":"2021120905302672200_R21","doi-asserted-by":"crossref","unstructured":"Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol.\u20081997;39(4):214\u2013223","DOI":"10.1111\/j.1469-8749.1997.tb07414.x"},{"key":"2021120905302672200_R22","unstructured":"Bayley N. Bayley Scales of Infant Development, Second Edition. San Antonio, TX: The Psychological Corporation; 1993"},{"key":"2021120905302672200_R23","doi-asserted-by":"crossref","unstructured":"Eicher DJ, Wagner CL, Katikaneni LP, et al. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. Pediatr Neurol.\u20082005;32(1):11\u201317","DOI":"10.1016\/j.pediatrneurol.2004.06.014"},{"key":"2021120905302672200_R24","doi-asserted-by":"crossref","unstructured":"Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res.\u20082007;61(4):451\u2013455","DOI":"10.1203\/pdr.0b013e3180332cec"},{"key":"2021120905302672200_R25","doi-asserted-by":"crossref","unstructured":"Villa P, van Beek J, Larsen AK, et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab.\u20082007;27(3):552\u2013563","DOI":"10.1038\/sj.jcbfm.9600370"},{"key":"2021120905302672200_R26","doi-asserted-by":"crossref","unstructured":"Keller M, Yang J, Griesmaier E, et al. Erythropoietin is neuroprotective against NMDA-receptor-mediated excitotoxic brain injury in newborn mice. Neurobiol Dis.\u20082006;24(2):357\u2013366","DOI":"10.1016\/j.nbd.2006.07.007"},{"key":"2021120905302672200_R27","unstructured":"US Food and Drug Administration. Early communication about an ongoing safety review: epoetin alfa. Available at: www.fda.gov\/cder\/drug\/early_comm\/epoetin_alfa.htm. Accessed February 20, 2009"},{"key":"2021120905302672200_R28","doi-asserted-by":"crossref","unstructured":"Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate.\u20082004;85(2):138\u2013144","DOI":"10.1159\/000074970"},{"key":"2021120905302672200_R29","doi-asserted-by":"crossref","unstructured":"Xenocostas A, Cheung WK, Farrell F, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol.\u20082005;61(3):189\u2013195","DOI":"10.1007\/s00228-005-0896-7"},{"key":"2021120905302672200_R30","doi-asserted-by":"crossref","unstructured":"Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res.\u20081999;46(5):543\u2013547","DOI":"10.1203\/00006450-199911000-00009"},{"key":"2021120905302672200_R31","unstructured":"Chen N, Mao J, Du Y. Erythropoietin levels in serum and cerebrospinal fluid of neonates with hypoxic-ischemic encephalopathy. Chin J Contemp Pediatr.\u20082005;7(2):107\u2013111"},{"key":"2021120905302672200_R32","doi-asserted-by":"crossref","unstructured":"Melo AM, Costa MT, Porta V, Vaz FA. Clinical pharmacokinetics of lyophilized recombinant human erythropoietin-\u03b1 following single-dose subcutaneous administration in premature newborns. J Matern Fetal Neonatal Med.\u20082005;17(1):55\u201358","DOI":"10.1080\/14767050400013420"},{"key":"2021120905302672200_R33","doi-asserted-by":"crossref","unstructured":"Ehrenreich H, Degner D, Meller J, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry.\u20082004;9(1):42\u201354","DOI":"10.1038\/sj.mp.4001442"},{"key":"2021120905302672200_R34","doi-asserted-by":"crossref","unstructured":"Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther.\u20082001;298(2):820\u2013824","DOI":"10.1016\/S0022-3565(24)29444-1"},{"key":"2021120905302672200_R35","doi-asserted-by":"crossref","unstructured":"Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res.\u20082007;61(6):671\u2013675","DOI":"10.1203\/pdr.0b013e31805341dc"},{"key":"2021120905302672200_R36","doi-asserted-by":"crossref","unstructured":"Sire\u0301n AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A.\u20082001;98(7):4044\u20134049","DOI":"10.1073\/pnas.051606598"},{"key":"2021120905302672200_R37","doi-asserted-by":"crossref","unstructured":"Gonzalez FF, McQuillen P, Mu D, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci.\u20082007;29(4\u20135):321\u2013330","DOI":"10.1159\/000105473"},{"key":"2021120905302672200_R38","doi-asserted-by":"crossref","unstructured":"Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med.\u20082003;198(6):971\u2013975","DOI":"10.1084\/jem.20021067"},{"key":"2021120905302672200_R39","doi-asserted-by":"crossref","unstructured":"Zhu C, Wang X, Xu F, et al. The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ.\u20082005;12(2):162\u2013176","DOI":"10.1038\/sj.cdd.4401545"},{"key":"2021120905302672200_R40","doi-asserted-by":"crossref","unstructured":"Ferriero DM. Neonatal brain injury. N Engl J Med.\u20082004;351(19):1985\u20131995","DOI":"10.1056\/NEJMra041996"},{"key":"2021120905302672200_R41","doi-asserted-by":"crossref","unstructured":"Edwards AD, Yue X, Cox P, et al. Apoptosis in the brains of infants suffering intrauterine cerebral injury. Pediatr Res.\u20081997;42(5):684\u2013689","DOI":"10.1203\/00006450-199711000-00022"},{"key":"2021120905302672200_R42","doi-asserted-by":"crossref","unstructured":"Zhu C, Wang X, Huang Z, et al. Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ.\u20082007;14(4):775\u2013784","DOI":"10.1038\/sj.cdd.4402053"},{"key":"2021120905302672200_R43","doi-asserted-by":"crossref","unstructured":"Raber J, Fan Y, Matsumori Y, et al. Irradiation attenuates neurogenesis and exacerbates ischemia-induced deficits. Ann Neurol.\u20082004;55(3):381\u2013389","DOI":"10.1002\/ana.10853"},{"key":"2021120905302672200_R44","doi-asserted-by":"crossref","unstructured":"Naylor AS, Bull C, Nilsson MK, et al. Voluntary running rescues adult hippocampal neurogenesis after irradiation of the young mouse brain. Proc Natl Acad Sci U S A.\u20082008;105(38):14632\u201314637","DOI":"10.1073\/pnas.0711128105"},{"key":"2021120905302672200_R45","doi-asserted-by":"crossref","unstructured":"Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I\/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics.\u20082008;122(2):383\u2013391","DOI":"10.1542\/peds.2007-2711"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/2\/e218\/1103627\/zpe0080900e218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/2\/e218\/1103627\/zpe0080900e218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T07:52:16Z","timestamp":1739260336000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/124\/2\/e218\/72400\/Erythropoietin-Improved-Neurologic-Outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,1]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,8,1]]},"published-print":{"date-parts":[[2009,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-3553","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718213343.793488818","asserted-by":"object"}]},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,1]]}}}